The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Researchers Seek ANCA-Associated Vasculitis Subtype Markers

Researchers Seek ANCA-Associated Vasculitis Subtype Markers

October 19, 2020 • By Larry Beresford

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Drugs Under Development

Current drugs and those under development target the complement system, Dr. Wu says. “Naturally, we’re interested in looking at the place for these medications as potential treatments for ANCA-associated vasculitis.” These include eculizumab, which was developed by Alexion and works by selectively inhibiting complement component C5, and avacopan, an orally administered drug candidate developed by ChemoCentryx that inhibits the C5a receptor.

You Might Also Like
  • Researchers Seek the Best Methods to Maintain Remission in Vasculitis
  • Research Shows Genetic Links in ANCA-Associated Vasculitis
  • ANCA-Associated Vasculitis Trial Results May Change Standard of Care
Explore This Issue
October 2020
Also By This Author
  • Identifying Cardiovascular Risk Factors in Psoriatic Arthritis

“We are excited about the direction we are going, with ongoing projects to longitudinally follow a group of ANCA-associated vasculitis patients with a spectrum of disease manifestations to see if complement activation can reliably predict or correlate with disease activity, disease remission and treatment response,” Dr. Wu says.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The clinical implications aren’t clear yet. “We need to better understand the role of complement activation in the emergence of disease using mechanistic studies. We know it’s important, but don’t fully understand its clinical applications yet.” she says. “Can we predict which patients might benefit from a particular treatment? What is on the horizon is answering if complement-targeting therapy would be helpful to all ANCA-associated vasculitis patients, or just a subset, and could that subset be identified sooner.” 


Larry Beresford is a medical journalist in Oakland, Calif.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Wu EY, McInnis EA, Suavet SB, et al. Measuring circulating complement activation products in myeloperoxidase and proteinase 3 antineutrophil cytoplasmic antibody vasculitis. Arthritis Rheumatol. 2019 Nov;71(11):1894–1903.
  2. Jennette JC, Xiao H, Falk R, et al. Experimental models of vasculitis and glomerulonephritis induced by antineutrophil cytoplasmic autoantibodies. Contrib Nephrol. 2011;169:211–220.
  3. Chen M, Daha MR, Kallenberg CGM. The complement system in systemic autoimmune disease. J Autoimmun. 2010 May;34(3):J276–J286.

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Vasculitis Tagged With: avacopan, Biomarkers, complement activation, eculizumabIssue: October 2020

You Might Also Like:
  • Researchers Seek the Best Methods to Maintain Remission in Vasculitis
  • Research Shows Genetic Links in ANCA-Associated Vasculitis
  • ANCA-Associated Vasculitis Trial Results May Change Standard of Care
  • ANCA-Associated Vasculitis in Systemic Sclerosis

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.